Monoclonal antibodies (mAbs) have exhibited substantial potential as targeted therapeutics in cancer treatment due to their precise antigen-binding specificity. Despite their success in tumor-targeted therapies, their effectiveness is hindered by their large size and limited tissue permeability. Camelid-derived single-domain antibodies, also known as nanobodies, represent the smallest naturally occurring antibody fragments. Nanobodies offer distinct advantages over traditional mAbs, including their smaller size, high stability, lower manufacturing costs, and deeper tissue penetration capabilities. They have demonstrated significant roles as both diagnostic and therapeutic tools in cancer research and are also considered as the next generation of antibody drugs. In this review, our objective is to provide readers with insights into the development and various applications of nanobodies in the field of cancer treatment, along with an exploration of the challenges and strategies for their prospective clinical trials.
单克隆抗体因其精确的抗原结合特异性，在癌症靶向治疗领域展现出巨大潜力。尽管其在肿瘤靶向治疗中已取得显著成效，但其大分子结构及有限的组织渗透性仍制约了疗效发挥。骆驼源单域抗体，亦称纳米抗体，是目前已知最小的天然抗体片段。与传统单克隆抗体相比，纳米抗体具有尺寸小、稳定性高、生产成本低及组织穿透性强等独特优势。其在癌症研究中已展现出作为诊断与治疗工具的重要价值，并被视为下一代抗体药物。本文旨在系统阐述纳米抗体在癌症治疗领域的发展历程与应用进展，同时探讨其未来临床试验面临的挑战与应对策略。
Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics
肿瘤(癌症)患者之家